Literature DB >> 8150553

Effects of oral administration of Lactobacillus casei on antitumor responses induced by tumor resection in mice.

I Kato1, K Endo, T Yokokura.   

Abstract

The effects of an oral administration of BLP, a preparation of viable Lactobacillus casei YIT 9018, upon tumor growth and the mitogenic responses of splenocytes from tumor-bearing mice were studied. BALB/c mice were insufficiently pre-immunized by resecting a Colon 26 tumor mass (primary tumor) grown for 5 days intradermally. Thereafter, mice were rechallenged by injecting Colon 26 tumor (secondary tumor) into the hind footpad. The secondary tumor grew progressively in control mice, but was markedly suppressed by oral administration with BLP at a dose of 100 or 200 mg/kg/day for 7 consecutive days. The suppression was a primary tumor-specific response. Viable L. casei, not heat-killed L. casei, could suppress the secondary tumor. Although the lymphoproliferative responses of splenocytes from the secondary tumor-bearing mice with T-cell mitogens (concanavalin A and phytohaemagglutinin) and cytokines (interleukin-1 and interleukin-2) were lower than those of normal mice, this suppression of mitogenic responses under tumor-bearing conditions was abolished by oral administration with BLP. Thus we concluded that oral BLP potentiated systemic immune responses that modified T-cell functions in tumor-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8150553     DOI: 10.1016/0192-0561(94)90116-3

Source DB:  PubMed          Journal:  Int J Immunopharmacol        ISSN: 0192-0561


  19 in total

1.  Development of a structured model for batch cultures of lactic acid bacteria.

Authors:  M A Del Nobile; C Altieri; M R Corbo; M Sinigaglia; E La Notte
Journal:  J Ind Microbiol Biotechnol       Date:  2003-07-09       Impact factor: 3.346

Review 2.  Intestinal microbiome and lymphoma development.

Authors:  Mitsuko L Yamamoto; Robert H Schiestl
Journal:  Cancer J       Date:  2014 May-Jun       Impact factor: 3.360

Review 3.  Traditional healthful fermented products of Japan.

Authors:  Yoshikatsu Murooka; Mitsuo Yamshita
Journal:  J Ind Microbiol Biotechnol       Date:  2008-05-07       Impact factor: 3.346

Review 4.  Anticancer effects of the microbiome and its products.

Authors:  Laurence Zitvogel; Romain Daillère; María Paula Roberti; Bertrand Routy; Guido Kroemer
Journal:  Nat Rev Microbiol       Date:  2017-05-22       Impact factor: 60.633

5.  Lactobacilli from human gastrointestinal mucosa are strong stimulators of IL-12 production.

Authors:  C Hessle; L A Hanson; A E Wold
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

Review 6.  Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges.

Authors:  S Salminen; E Isolauri; E Salminen
Journal:  Antonie Van Leeuwenhoek       Date:  1996-10       Impact factor: 2.271

7.  Recombinant Lactobacillus plantarum inhibits house dust mite-specific T-cell responses.

Authors:  A Kruisselbrink; M J Heijne Den Bak-Glashouwer; C E Havenith; J E Thole; R Janssen
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

8.  Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer.

Authors:  Marion Lenoir; Silvina Del Carmen; Naima G Cortes-Perez; Daniel Lozano-Ojalvo; Diego Muñoz-Provencio; Florian Chain; Philippe Langella; Alejandra de Moreno de LeBlanc; Jean Guy LeBlanc; Luis G Bermúdez-Humarán
Journal:  J Gastroenterol       Date:  2016-01-09       Impact factor: 7.527

9.  Live and heat-inactivated lactobacilli from feces inhibit Salmonella typhi and Escherichia coli adherence to Caco-2 cells.

Authors:  S N Ostad; A A Salarian; M H Ghahramani; M R Fazeli; N Samadi; H Jamalifar
Journal:  Folia Microbiol (Praha)       Date:  2009-05-06       Impact factor: 2.099

10.  Growth inhibition of hepatocellular carcinoma Huh7 cells by Lactobacillus casei extract.

Authors:  Dae Jong Han; Jong Bin Kim; Seo Young Park; Man Gil Yang; Hyuncheol Kim
Journal:  Yonsei Med J       Date:  2013-09       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.